Serial T1 and T2 measurements of metastatic bone lesions in prostate cancer patients: MR fingerprinting vs conventional MRI - Takeaways - MDSpire

Serial T1 and T2 measurements of metastatic bone lesions in prostate cancer patients: MR fingerprinting vs conventional MRI

  • By

  • Mihaela Rata

  • Nina Tunariu

  • Yun Jiang

  • Julie Hughes

  • Georgina Hopkinson

  • Erica Scurr

  • Jessica M. Winfield

  • Vikas Gulani

  • Dow-Mu Koh

  • Matthew R. Orton

  • October 24, 2025

  • 0 min

Share

  • 1

    Magnetic resonance fingerprinting (MRF) improves the efficiency of quantitative imaging for T1 and T2 measurements in metastatic bone lesions.

  • 2

    This study evaluated MRF-derived T1 and T2 changes in prostate cancer patients with metastatic bone disease before and after treatment.

  • 3

    MRF offers high repeatability and reproducibility, making it a promising tool for assessing treatment response in metastatic bone disease.

  • 4

    Conventional MRI methods for T1 and T2 measurement are impractical due to long acquisition times, highlighting MRF's time efficiency.

  • 5

    The study included 34 prostate cancer patients, with 19 undergoing follow-up scans to assess treatment response using MRF.

Original Source(s)

Serial T1 and T2 measurements of metastatic bone lesions in prostate cancer patients: MR fingerprinting vs conventional MRI

  • by Mihaela Rata, Nina Tunariu, Yun Jiang, Julie Hughes, Georgina Hopkinson, Erica Scurr, Jessica M. Winfield, Vikas Gulani, Dow-Mu Koh, Matthew R. Orton

  • October 24, 2025

Related Content

Large language model-based uncertainty-adjusted label extraction for artificial intelligence model development in upper extremity radiography

AI in radiology and interventions: a structured narrative review of workflow automation, accuracy, and efficiency gains of today and what’s coming

LV Function Mostly Preserved After ASO

CMR findings were largely reassuring in most patients, although late gadolinium enhancement was identified in a minority.